VYNE Therapeutics Inc.

Healthcare · Biotechnology · United States

Last price 28.56 USD (At close: Jul 27, 2026) · Market cap 19.05M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

As of July 27, 2026, VYNE Therapeutics Inc. was acquired by Yarrow Bioscience, Inc., in a reverse merger transaction. VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company’s lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure...